PA
LXRX icon

Perceptive Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Perceptive Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$718K – 210
2016
Q2 		$718K Buy
+50,000
New +$678K 0.05% 103

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors's LXRX Position: Q3 2016 in Review

Perceptive Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 50,000 shares — an estimated $718K sold.

Perceptive Advisors first reported a position in LXRX in Q2 2016 and held it in 1 quarter. The position peaked at $718K in Q2 2016. 144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • Perceptive Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Perceptive Advisors sold 50,000 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $718K.
  • Perceptive Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Perceptive Advisors's Lexicon Pharmaceuticals position peaked at $718K in Q2 2016.
  • 144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.